Analyst Price Target is $74.62
▲ +41.75% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Immunocore in the last 3 months. The average price target is $74.62, with a high forecast of $91.00 and a low forecast of $16.00. The average price target represents a 41.75% upside from the last price of $52.64.
Current Consensus is
The current consensus among 14 investment analysts is to moderate buy stock in Immunocore. This Moderate Buy consensus rating has held steady for over two years.
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.